Thomas Wilder Sells 186 Shares of Penumbra (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder sold 186 shares of Penumbra stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $310.72, for a total transaction of $57,793.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Penumbra Stock Performance

NYSE PEN traded up $0.96 during trading hours on Tuesday, hitting $315.96. 623,275 shares of the stock were exchanged, compared to its average volume of 387,949. The company has a quick ratio of 4.18, a current ratio of 6.73 and a debt-to-equity ratio of 0.02. The company has a market cap of $12.37 billion, a price-to-earnings ratio of 75.59, a price-to-earnings-growth ratio of 1.92 and a beta of 0.71. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $321.38. The stock has a 50-day moving average of $289.92 and a 200 day moving average of $265.84.

Penumbra (NYSE:PEN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.07. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.The company had revenue of $354.69 million for the quarter, compared to analyst estimates of $340.77 million. During the same quarter in the previous year, the company earned $0.85 EPS. The firm’s revenue for the quarter was up 17.8% compared to the same quarter last year. As a group, equities research analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PEN. Robert W. Baird set a $345.00 target price on Penumbra in a report on Tuesday, December 16th. Citigroup raised shares of Penumbra from a “neutral” rating to a “buy” rating and increased their price objective for the company from $285.00 to $350.00 in a research note on Thursday, December 11th. Wells Fargo & Company began coverage on shares of Penumbra in a research report on Tuesday, November 18th. They set an “underweight” rating for the company. JPMorgan Chase & Co. upgraded shares of Penumbra from a “neutral” rating to an “overweight” rating and increased their price target for the company from $275.00 to $370.00 in a research report on Thursday, December 18th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Penumbra in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $340.40.

Institutional Trading of Penumbra

A number of hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. grew its holdings in Penumbra by 1,139.3% in the 2nd quarter. Invesco Ltd. now owns 633,485 shares of the company’s stock valued at $162,571,000 after buying an additional 582,369 shares during the period. Norges Bank acquired a new stake in shares of Penumbra in the second quarter worth approximately $114,014,000. Holocene Advisors LP purchased a new stake in Penumbra in the third quarter valued at approximately $78,585,000. Qube Research & Technologies Ltd purchased a new stake in Penumbra in the second quarter valued at approximately $53,818,000. Finally, Man Group plc increased its position in Penumbra by 1,862.2% during the second quarter. Man Group plc now owns 206,461 shares of the company’s stock worth $52,984,000 after purchasing an additional 195,939 shares during the last quarter. 88.88% of the stock is owned by institutional investors and hedge funds.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.